Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?

BMC Endocrine Disorders

Volumn 13, Issue , 2013, Pages

  Balbach, Lisa ^a   Wallaschofski, Henri ^a,b   Völzke, Henry ^a,b   Nauck, Matthias ^a,b   Dörr, Marcus ^a,b   Haring, Robin ^a,b  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROLACTIN; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; EDUCATIONAL STATUS; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PARITY; PHYSICAL ACTIVITY; POPULATION RESEARCH; PROLACTIN BLOOD LEVEL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84875145729     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-13-12     Document Type: Article

References (46)

1. Cejkova P, Fojtikova M, Cerna M. Immunomodulatory role of prolactin in diabetes development. Autoimmun Rev 2009, 9(1):23-27. 10.1016/j.autrev.2009.02.031, 19248843.
2. Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab 2007, 9(4):464-476. 10.1111/j.1463-1326.2006.00671.x, 17587388.
3. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends in endocrinology and metabolism. TEM 2006, 17(3):110-116.
4. Prasad H, Ryan DA, Celzo MF, Stapleton D. Metabolic syndrome: definition and therapeutic implications. Postgrad Med 2012, 124(1):21-30. 10.3810/pgm.2012.01.2514, 22913891.
5. Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, Kawamori R. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol 2008, 93(10):3671-3689.
6. Brelje TC, Stout LE, Bhagroo NV, Sorenson RL. Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of langerhans. Endocrinology 2004, 145(9):4162-4175. 10.1210/en.2004-0201, 15142985.
7. Freemark M, Avril I, Fleenor D, Driscoll P, Petro A, Opara E, Kendall W, Oden J, Bridges S, Binart N. Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance. Endocrinology 2002, 143(4):1378-1385. 10.1210/en.143.4.1378, 11897695.
8. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 2006, 64(4):366-370.
9. Mingrone G, Manco M, Iaconelli A, Gniuli D, Bracaglia R, Leccesi L, Calvani M, Nolfe G, Basu S, Berria R. Prolactin and insulin ultradian secretion and adipose tissue lipoprotein lipase expression in severely obese women after bariatric surgery. Obesity (Silver Spring) 2008, 16(8):1831-1837.
10. Ernst B, Thurnheer M, Schultes B. Basal serum prolactin levels in obesity-unrelated to parameters of the metabolic syndrome and unchanged after massive weight loss. Obes Surg 2009, 19(8):1159-1162. 10.1007/s11695-009-9856-0, 19430852.
11. Corona G, Rastrelli G, Boddi V, Monami M, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. Int J Androl 2011, 34(3):217-224. 10.1111/j.1365-2605.2010.01076.x, 20522124.
12. Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G. Cohort profile: the study of health in pomerania. Int J Epidemiol 2011, 40(2):294-307. 10.1093/ije/dyp394, 20167617.
13. Haring R, Alte D, Volzke H, Sauer S, Wallaschofski H, John U, Schmidt CO. Extended recruitment efforts minimize attrition but not necessarily bias. J Clin Epidemiol 2009, 62(3):252-260. 10.1016/j.jclinepi.2008.06.010, 18834716.
14. Torkler S, Wallaschofski H, Baumeister SE, Volzke H, Dorr M, Felix S, Rettig R, Nauck M, Haring R. Inverse association between total testosterone concentrations, incident hypertension and blood pressure. Aging Male 2011, 14(3):176-182. 10.3109/13685538.2010.529194, 21087174.
15. Haring R, Hannemann A, John U, Radke D, Nauck M, Wallaschofski H, Owen L, Adaway J, Keevil BG, Brabant G. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metabol 2012, 97(2):408-415.
16. Nauck M, Winkler K, Marz W, Wieland H. Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem 1995, 41(12 Pt 1):1761-1767.
17. Haring R, Baumeister SE, Völzke H, Dorr M, Felix SB, Kroemer HK, Nauck M, Wallaschofski H. Prospective Association of Low Total Testosterone Concentrations with an Adverse Lipid Profile and Increased Incident Dyslipidemia. Eur J Cardiovasc Prev Rehabil 2011, 18(1):86-96.
18. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645. 10.1161/CIRCULATIONAHA.109.192644, 19805654.
19. Hannemann A, Meisinger C, Bidlingmaier M, Doring A, Thorand B, Heier M, Belcredi P, Ladwig KH, Wallaschofski H, Friedrich N. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol 2011, 164(5):751-758. 10.1530/EJE-10-1074, 21357289.
20. Schipf S, Alte D, Voelzke H, Friedrich N, Haring R, Lohmann T, Nauck M, Felix SB, Hoffmann W, John U. Prävalenz des Metabolischen Syndroms in Deutschland: Ergebnisse der Study of Health in Pomerania (SHIP). Diabetologie Stoffwechsel 2010, 5:161-168.
21. Haring R, Volzke H, Felix SB, Schipf S, Dorr M, Rosskopf D, Nauck M, Schofl C, Wallaschofski H. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes 2009, 58(9):2027-2031. 10.2337/db09-0031, 2731522, 19581420.
22. Haring R, Wallaschofski H, Nauck M, Felix SB, Schmidt CO, Dorr M, Sauer S, Wilmking G, Volzke H. Total and cardiovascular disease mortality predicted by metabolic syndrome is inferior relative to its components. Exp Clin Endocrinol Diabetes 2010, 118(10):685-691. 10.1055/s-0030-1261876, 20625974.
23. Lidfeldt J, Nyberg P, Nerbrand C, Samsioe G, Schersten B, Agardh CD. Socio-demographic and psychosocial factors are associated with features of the metabolic syndrome. The Women's Health in the Lund Area (WHILA) study. Diabetes Obes Metab 2003, 5(2):106-112. 10.1046/j.1463-1326.2003.00250.x, 12630935.
24. Molitch ME. Drugs and prolactin. Pituitary 2008, 11(2):209-218. 10.1007/s11102-008-0106-6, 18404390.
25. Afifi AA, Kotlerman JB, Ettner SL, Cowan M. Methods for improving regression analysis for skewed continuous or counted responses. Annu Rev Public Health 2007, 28:95-111. 10.1146/annurev.publhealth.28.082206.094100, 17112339.
26. Corona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M, Boddi V, Bandini E, Balercia G, Forti G. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med 2009, 6(5):1457-1466. 10.1111/j.1743-6109.2008.01206.x, 19210705.
27. Muldoon MF, Mackey RH, Korytkowski MT, Flory JD, Pollock BG, Manuck SB. The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. J Clin Endocrinol Metabol 2006, 91(2):718-721.
28. Meaney AM, O'Keane V. Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci 2002, 71(9):979-992. 10.1016/S0024-3205(02)01775-7, 12088758.
29. Rao ML, Gross G, Strebel B, Halaris A, Huber G, Braunig P, Marler M. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatry 1994, 35(3):151-163. 10.1016/0006-3223(94)91147-9, 7909693.
30. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003, 160(2):284-289. 10.1176/appi.ajp.160.2.284, 12562574.
31. Oberweis B, Gragnoli C. Potential role of prolactin in antipsychotic-mediated association of schizophrenia and type 2 diabetes. J Cell Physiol 2012, 227(8):3001-3006. 10.1002/jcp.24023, 22105468.
32. Muldoon MF, Mackey RH, Williams KV, Korytkowski MT, Flory JD, Manuck SB. Low central nervous system serotonergic responsivity is associated with the metabolic syndrome and physical inactivity. J Clin Endocrinol Metabol 2004, 89(1):266-271.
33. Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011, 14(3):199-207. 10.1007/s11102-010-0277-9, 21128120.
34. dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 2011, 19(4):800-805.
35. Weinhaus AJ, Stout LE, Bhagroo NV, Brelje TC, Sorenson RL. Regulation of glucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy. J Endocrinol 2007, 193(3):367-381. 10.1677/JOE-07-0043, 17535875.
36. Yamamoto T, Ricordi C, Mita A, Miki A, Sakuma Y, Molano RD, Fornoni A, Pileggi A, Inverardi L, Ichii H. beta-Cell specific cytoprotection by prolactin on human islets. Transplant Proc 2008, 40(2):382-383. 10.1016/j.transproceed.2008.01.009, 2614218, 18374075.
37. Yamamoto T, Mita A, Ricordi C, Messinger S, Miki A, Sakuma Y, Timoneri F, Barker S, Fornoni A, Molano RD. Prolactin supplementation to culture medium improves beta-cell survival. Transplantation 2010, 89(11):1328-1335. 10.1097/TP.0b013e3181d98af1, 20357700.
38. Terra LF, Garay-Malpartida MH, Wailemann RA, Sogayar MC, Labriola L. Recombinant human prolactin promotes human beta cell survival via inhibition of extrinsic and intrinsic apoptosis pathways. Diabetologia 2011, 54(6):1388-1397. 10.1007/s00125-011-2102-z, 21394492.
39. Friedrich N, Schneider HJ, Spielhagen C, Markus MR, Haring R, Grabe HJ, Buchfelder M, Wallaschofski H, Nauck M. The association of serum prolactin concentration with inflammatory biomarkers - cross-sectional findings from the population-based Study of Health in Pomerania. Clin Endocrinol (Oxf) 2011, 75(4):561-566.
40. Haring R, Friedrich N, Volzke H, Vasan RS, Felix SB, Dorr M, Meyer Zu Schwabedissen HE, Nauck M, Wallaschofski H. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur Heart J 2012,
41. Haring R, Volzke H, Vasan RS, Felix SB, Nauck M, Dorr M, Wallaschofski H. Sex-specific associations of serum prolactin concentrations with cardiac remodeling: longitudinal results from the Study of Health Pomerania (SHIP). Atherosclerosis 2012, 221(2):570-576. 10.1016/j.atherosclerosis.2012.01.017, 22293228.
42. Katznelson L, Riskind PN, Saxe VC, Klibanski A. Prolactin pulsatile characteristics in postmenopausal women. J Clin Endocrinol Metabol 1998, 83(3):761-764.
43. Maratou E, Hadjidakis DJ, Peppa M, Alevizaki M, Tsegka K, Lambadiari V, Mitrou P, Boutati E, Kollias A, Economopoulos T. Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism. Eur J Endocrinol 2010, 163(4):625-630. 10.1530/EJE-10-0246, 20643758.
44. Mitrou P, Raptis SA, Dimitriadis G. Insulin action in hyperthyroidism: a focus on muscle and adipose tissue. Endocr Rev 2010, 31(5):663-679. 10.1210/er.2009-0046, 20519325.
45. Resmini E, Minuto F, Colao A, Ferone D. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol 2009, 46(2):85-95. 10.1007/s00592-009-0112-9, 19322513.
46. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health 2005, 95(Suppl 1):S144-150.